Newsfeeds - Spark Newswire

8 minute read

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs

Today, 8:20 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)

ABIO

2 minute read

Stealth BioTherapeutics Reports SBT-272 Preclinical Data At Northeast Amyotrophic Lateral Sclerosis Meeting

By Benzinga Newsdesk

Today, 8:20 AM

Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction,

MITO

2 minute read

News

Stealth BioTherapeutics Presents Elamipretide Data In Pediatric Cardiology At International Society For Heart Research North American Section Meeting 2021

By Benzinga Newsdesk

Today, 8:20 AM

MITO

1 minute read

Stealth Bio Posts Encouraging Preclinical Data In Parkinson’s Animal Studies

By Vandana Singh

Today, 8:20 AM

Stealth BioTherapeutics Corp (NASDAQ:MITO) has presented new data from a study evaluating SBT-272 in a murine model of Parkinson’s disease (PD). …

MITO

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 8:20 AM

Gainers

ADXS

3 minute read

38 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 8:20 AM

Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.

ADGI

3 minute read

26 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 8:20 AM

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) rose 46.1% to $0.6699 in pre-market trading after dropping 11% on Tuesday.

ATNX

1 minute read

Stealth Bio Files US Application For Ultra Rare Genetic Disease Candidate

By Vandana Singh

Today, 8:20 AM

Stealth BioTherapeutics Corp (NASDAQ:MITO) has submitted an elamipretide marketing application to the FDA for Barth syndrome. The submission is based on…

MITO

1 minute read

Stealth BioTherapeutics Announces Issuance Of US Patents Covering Elamipretide For Barth Syndrome

By Bill Haddad

Today, 8:20 AM

Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today

MITO

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 8:20 AM

Gainers

CASI